| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00292071 | Fungal Infection | Drug: caspofungin acetate | Merck Sharp & Dohme Corp. | Phase 2 | 2004-05-01 | 2017-02-20 |
| NCT00635648 | Fungal Infection | Drug: caspofungin acetate | Merck Sharp & Dohme Corp. | Phase 3 | 2008-01-01 | 2017-02-21 |
| NCT01533558 | Invasive Fungal Infection | Drug: caspofungin | Radboud University | | 2012-01-01 | 2013-08-28 |
| NCT00404092 | Invasive Aspergillosis | Drug: caspofungin | University of Cologne | Phase 2 | 2006-10-01 | 2013-07-25 |
| NCT02596984 | Shock | Drug: Caspofungin | Centre Hospitalier Universitaire de Saint Etienne|Merck Sharp & Dohme Corp. | | 2015-03-01 | 2016-11-09 |
| NCT00748345 | Thermal Injury | Drug: Caspofungin (drug) | Assistance Publique - Hôpitaux de Paris | Phase 2|Phase 3 | 2009-02-01 | 2011-12-15 |
| NCT01968395 | Bacterial Infections and Mycoses|Liver Disease | Drug: Caspofungin 70 mg | Erasme University Hospital | Phase 4 | 2013-09-01 | 2013-10-23 |
| NCT01318148 | Fungal Infection | Drug: caspofungin | Werner J. Heinz|Merck Sharp & Dohme Corp.|Wuerzburg University Hospital | Phase 2 | 2011-04-01 | 2014-01-08 |
| NCT00330395 | Candidiasis | Drug: caspofungin acetate | Merck Sharp & Dohme Corp. | Phase 2 | 2006-05-01 | 2017-02-20 |
| NCT01062165 | Obesity|Fungal Infection | Drug: Caspofungin | Texas Tech University Health Sciences Center|National Center for Research Resources (NCRR)|University of Texas Southwestern Medical Center | Phase 4 | 2010-02-01 | 2016-12-21 |
| NCT01499433 | Invasive Pulmonary Aspergillosis|Chronic Obstructive Pulmonary Disease | Drug: caspofungin | The First Affiliated Hospital of Guangzhou Medical University|Merck Sharp & Dohme Corp. | Phase 4 | 2012-01-01 | 2014-01-22 |
| NCT01045798 | Invasive Candidiasis | Drug: Caspofungin acetate|Drug: Placebo | Merck Sharp & Dohme Corp.|Mycoses Study Group | Phase 2 | 2010-12-01 | 2017-02-21 |
| NCT00238355 | Infection|Unspecified Adult Solid Tumor, Protocol Specific | Drug: caspofungin acetate|Drug: voriconazole | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Phase 2 | 2003-08-01 | 2011-12-12 |
| NCT00388167 | Candidiasis|Aspergillosis | Drug: Caspofungin | PETHEMA Foundation|GTEI|SEMICYUC | Phase 4 | 2004-03-01 | 2009-05-11 |
| NCT02510053 | Invasive Fungal Infection | Drug: Caspofungin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | | 2014-07-01 | 2015-07-26 |
| NCT01994096 | Critically Ill|Suspected Invasive Candidiasis | Drug: Caspofungin | University Medical Center Groningen | Phase 4 | 2013-11-01 | 2015-10-29 |
| NCT00082537 | Neutropenia|Fever | Drug: caspofungin acetate|Drug: Comparator: AmBisome | Merck Sharp & Dohme Corp. | Phase 2 | 2004-04-01 | 2017-02-20 |
| NCT01503515 | Fungal Infection|Hematopoietic/Lymphoid Cancer | Drug: caspofungin acetate|Drug: fluconazole|Drug: voriconazole|Other: laboratory biomarker analysis | Children's Oncology Group|National Cancer Institute (NCI) | Phase 3 | 2013-03-01 | 2017-01-18 |
| NCT00095316 | Candidiasis | Drug: Caspofungin|Other: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2004-10-01 | 2014-12-04 |
